Figure 4
Figure 4. Development of MCL in EμCycD1CD19CREBimfl/fl mice treated with SRBC and pristane. (A-C) Disease manifestations of distinct EμCycD1CD19CREBimfl/fl mice. First row: Flow cytometry of splenic mononuclear cells (y-axis B220, x-axis CD5). Second row: Flow cytometric analysis of the B220+CD5+ cells for expression of CD23, plotted as a histogram. Third row: Hematoxylin and eosin staining of spleens (original magnification: ×1000). Fourth row: B220 immunohistochemistry (original magnification, left to right: ×20, ×40, ×40). Fifth row: cyclin D1 immunohistochemistry (original magnification, left to right: ×20, ×40, ×40). APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.

Development of MCL in EμCycD1CD19CREBimfl/flmice treated with SRBC and pristane. (A-C) Disease manifestations of distinct EμCycD1CD19CREBimfl/fl mice. First row: Flow cytometry of splenic mononuclear cells (y-axis B220, x-axis CD5). Second row: Flow cytometric analysis of the B220+CD5+ cells for expression of CD23, plotted as a histogram. Third row: Hematoxylin and eosin staining of spleens (original magnification: ×1000). Fourth row: B220 immunohistochemistry (original magnification, left to right: ×20, ×40, ×40). Fifth row: cyclin D1 immunohistochemistry (original magnification, left to right: ×20, ×40, ×40). APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal